A Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular Treatment
Part of paid clinical trials in Kissimmee, Florida.
- Sponsor
- Viatris Innovation GmbH
- Study ID
- NCT07201129
- Phase
- PHASE3
- Status
- Recruiting
Conditions
- Lupus Erythematosus, Systemic
- Nephritis, Lupus
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 75 Years
- Healthy Volunteers
- Not accepted
Interventions
- Cenerimod — DRUGCenerimod will be supplied as a film-coated tablets at the dose of 4 mg.
- Placebo — DRUGMatching placebo will be supplied as identical film-coated tablets formulated with the same excipients but without the active ingredient, cenerimod.
Study Details
The goal of this clinical trial is to learn if cenerimod, on top of regular treatment, works to treat active lupus nephritis in adults with systemic lupus erythematosus and active lupus nephritis. It will also learn about the safety of cenerimod. The main questions it aims to answer are: * Does cenerimod improve kidney function in participants? * What medical problems do participants have when taking cenerimod? Researchers will compare cenerimod to a placebo (a look-alike substance that contains no drug) to see how well cenerimod works when it is added to regular treatment. Participants will: * Take cenerimod or a placebo every day for 76 weeks (approximately 1.5 years), on top of regular treatment. * Visit the clinic every 1 to 3 months for checkups and tests.
Key Dates
- Start date
- Feb 9, 2026
- Status verified
- Sep 2025
- Primary completion
- Aug 31, 2029
- Completion
- Feb 28, 2030
Study Design
- Enrollment
- 300 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Cenerimod 4 mgParticipants will receive cenerimod once daily in addition to background lupus nephritis (LN) therapy.
- Placebo Comparator: Matching placeboParticipants will receive matching placebo once daily in addition to background LN therapy.
Primary Outcome Measure
Complete renal response (CRR) [ Time Frame: At Week 76 ]
Central Contacts
- Viatris Innovation Clinical Trial Information+1 908 435 2675
Locations (11)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Alloy Clinical Research LLC | Kissimmee | Florida | 34741 | - |
| Allied Biomedical Research Institute | Miami | Florida | 33155 | - |
| DH NationalResearchCenters INC | Miami | Florida | 33155 | - |
| ProfessionalResearchCenter INC | Miami | Florida | 33172 | - |
| SouthCoast Research Center | Miami | Florida | 33136 | - |
| San Marcus Research Clinic, Inc. | Miami Lakes | Florida | 33014 | - |
| Rheumatology Care Center, PLLC | Bellaire | Texas | 77401 | - |
| Texas Arthritis Center | El Paso | Texas | 79902 | - |
| Northwest Houston Arthritis | Houston | Texas | 77090 | - |
| Novel Research, LLC. | Houston | Texas | 77024 | - |
| Discovery Clinical Trials LLC | San Antonio | Texas | 78229 | - |
Find similar trials in Kissimmee, FL
Related Studies
- Long-term Safety and Tolerability of Cenerimod in Adults With Systemic Lupus ErythematosusPHASE3 · Enrolling By Invitation · Viatris Innovation GmbH · Clearwater, Florida
- A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN)PHASE2 · Recruiting · Novartis Pharmaceuticals · Birmingham, Alabama
- A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLEPHASE1/PHASE2 · Recruiting · AstraZeneca · San Francisco, California
- A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)PHASE2 · Recruiting · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Scottsdale, Arizona